Trends in Medicare Spending on Drugs for Pulmonary Arterial Hypertension, 2012-2022

Annual estimated net Medicare spending on drugs to treat pulmonary arterial hypertension (PAH) more than doubled from $1.2 billion in 2012 to $2.8 billion in 2022, driven both by increased use and costs of the medications. By 2022, despite more generic availability, brand-name drugs still accounted for nearly 9 in every 10 dollars spent in Medicare on PAH medications.